Publications by authors named "E L Simoncini"
Article Synopsis
- * A new automated surface plasmon resonance (SPR)-based method was developed to track both AAA and ADL without requiring complex sample prep, allowing for multiple analyses with a single chip.
- * In a study with 47 ADL-treated patients, both SPR and ELISA methods detected AAA, achieving a 79% overall agreement, with noted differences in quantitative results, particularly in assessing ADL levels effectively.
Purpose: Although younger age has been negatively associated with persistence to adjuvant endocrine therapy (ET), factors contributing to non-persistence remain poorly understood. We assessed factors associated with non-persistence to ET and described the 5-year trajectories of quality of life (QoL) and symptoms in young women (≤40 years) with hormone receptor-positive breast cancer (BC).
Methods: We retrieved data on clinical characteristics and non-persistence from the medical annual records in the European cohort of the "Helping Ourselves, Helping Others: The Young Women's BC Study" (IBCSG 43-09 HOHO).
Purpose: The aim of the study was to analyze the modification of total and regional body composition in early breast cancer patients treated with aromatase inhibitors (AIs).
Methods: This is a prospective, single-center, observational, longitudinal study. Four-hundred and twenty-eight patients treated with adjuvant aromatase inhibitors were enrolled at the Medical Oncology and Breast Unit of Spedali Civili Hospital in Brescia from September 2014 to June 2022.
Article Synopsis
- The EVI1 gene is linked to a particularly aggressive form of acute myeloid leukemia (AML) characterized by abnormalities on chromosome 3q26.
- Selective and pan-histone deacetylase inhibitors (HDACis) have been identified as effective treatments for this type of leukemia by repressing EVI1 expression.
- The study suggests that the PA2G4 protein plays a key role in EVI1-related leukemia, and targeting PA2G4 could enhance the effects of HDACis, highlighting the potential for combination therapies in patients with 3q26 AML.